PRECEDENT: A randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer

Journal of Clinical Oncology

Volumn 31, Issue 35, 2013, Pages 4400-4406

  Naumann, R Wendel ^a   Coleman, Robert L ^b   Burger, Robert A ^d   Sausville, Edward A ^e   Kutarska, Elzbieta ^f   Ghamande, Sharad A ^h   Gabrail, Nashat Y ⁱ   DePasquale, Stephen E ^j   Nowara, Elzbieta ^g   Gilbert, Lucy ^k   Gersh, Robert H ^l   Teneriello, Michael G ^c   Harb, Wael A ^m   Konstantinopoulos, Panagiotis A ^o   Penson, Richard T ^p   Symanowski, James T ^a   Lovejoy, Chandra D ⁿ   Leamon, Christopher P ⁿ   Morgenstern, David E ⁿ   Messmann, Richard A ⁿ  

^a CAROLINAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEXAS ONCOLOGY   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f Centrum Onkologii Ziemi Lubelskiej   (United Kingdom)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ Gabrail Cancer Center   (United States)

^j Chattanooga's Program inwomen'Soncology   (United States)

^k MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^l Cancer Care Northwest   (United States)

^m Horizon Oncology Research Inc   (United States)

ⁿ Endocyte Inc   (United States)

^o Beth Israel Deaconess Medical Center   (Iceland)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; ETARFOLATIDE TC 99M; VINTAFOLIDE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EC20 FOLATE PEPTIDE; FOLIC ACID; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PLATINUM; VINCA ALKALOID;

ABDOMINAL PAIN; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLATINUM RESISTANT OVARIAN CANCER; POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMATITIS; THROMBOCYTOPENIA; ADULT; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG RESISTANCE; INTRAVENOUS ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; OVARIAN NEOPLASMS;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FOLIC ACID; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PLATINUM; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; VINCA ALKALOIDS;

EID: 84891854386     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.7685     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Bookman MA: Standard treatment in advanced ovarian cancer in 2005: The state of the art. Int J Gynecol Cancer 15:212-220, 2005 (suppl 3) (Pubitemid 43096584)
3. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007 (Pubitemid 47123191)
4. Reddy JA, Westrick E, Santhapuram HK, et al: Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. Cancer Res 67: 6376-6382, 2007 (Pubitemid 47037521)
5. Kalli KR, Oberg AL, Keeney GL, et al: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108:619-626, 2008
6. Toffoli G, Cernigoi C, Russo A, et al: Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198, 1997 (Pubitemid 27234510)
7. Reddy JA, Dorton R, Westrick E, et al: Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 67:4434-4442, 2007 (Pubitemid 46815093)
8. Rustin GJ, van der Burg ME: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 27: 5s, 2009 (suppl; abstr 1)
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
10. Lorusso PM, Edelman MJ, Bever SL, et al: Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors. J Clin Oncol 30:4011-4016, 2012
11. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocol Development/electronic-applications/docs/ ctcaev3.pdf
12. Lachin JM, Foulkes MA: Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to followup, noncompliance, and stratification. Biometrics 42:507-519, 1986
13. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982 (Pubitemid 13146129)
14. Naumann RW, Coleman RL, Burger RA, et al: PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 29: 343s, 2011 (suppl; abstr 5045)
15. Naumann RW, Symanowski JT, Ghamande SA, et al: PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 28:393s, 2010 (suppl; abstr LBA5012b)
16. Naumann RW, Coleman RL: Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397-1412, 2011
17. Sutton GP, Blessing JA, Barnes W, et al: Phase II study of vinblastine in previously treated squamous carcinoma of the cervix: A Gynecologic Oncology Group study. Am J Clin Oncol 13:470-471, 1990
18. Leamon CP: Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9:1277-1286, 2008